Skip to main content
. Author manuscript; available in PMC: 2024 Jul 10.
Published in final edited form as: Gynecol Oncol. 2022 Nov 18;168:92ā€“99. doi: 10.1016/j.ygyno.2022.11.001

Figure 2 ā€“

Figure 2 ā€“

(A) The percent of fluorescently labeled cells with rolling or (B) sticking/firm adhesion revealed no differences between controls and anti-VEGFR-2 treated groups, but statistically significant differences between carboplatin vs. anti-VEGFR-2 for rolling (p=0.035) and sticking (p=.0006) and anti-PD-1 vs. anti-VEGFR-2 for rolling (p=0.0015 ). Two-sided independent sample t-tests, significance pā‰¤0.05. (C) Representative photomicrographs of IVM video frames showing tumor vessels (white arrows), bleeding/vascular disruption (white arrowheads), and fluorescently labelled cells (black arrows).